Document Detail

Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition.
MedLine Citation:
PMID:  11441907     Owner:  NLM     Status:  MEDLINE    
Urotensin II (U-II) is a cyclic peptide, recently cloned in man and present in cardiac tissue and arteries. The effects of human U-II (hU-II) on coronary perfusion pressure (CPP) were investigated in isolated rat hearts perfused retrogradely via the aorta at constant flow. hU-II produced a concentration-dependent increase in CPP (pEC50 8.6 +/- 0.3, n = 8), the maximum increase in CPP (12 +/- 4 mmHg) was obtained at 10(-7) M hU-II. At higher concentrations of hU-II CPP fell back towards baseline. Endothelin-1 produced a maximum increase in CPP of 63 +/- 11 mmHg within the concentration-range studied. Addition of the NO synthase inhibitor L N(G)nitro-arginine methyl ester (10(-4) M) and the cyclooxygenase inhibitor, indomethacin (10(-5) M) to the perfusion solution had no effect on the pEC50 value for hU-II, but significantly increased the maximum constriction (to 34 +/- 7 mmHg, n = 8, p < 0.05) and inhibited the later dilator response to hU-II. These results suggest that receptors for hU-II are present in the coronary vasculature and that smooth muscle contraction is modulated by the release of dilator factors, including NO and prostacyclin. Endothelial function is therefore likely to be of primary importance in modulating the coronary vasoconstrictor effects of hU-II in vivo.
G A Gray; M R Jones; I Sharif
Related Documents :
21191547 - End organ damage in hypertension.
8419007 - Angiotensin ii directly stimulates release of atrial natriuretic factor in isolated rab...
1775567 - Blood pressure responses and drinking following central angiotensin ii in adult rats gu...
12680847 - Endothelin eta receptor antagonism does not attenuate angiotensin ii-induced cardiac hy...
3110937 - Gas composition of the normal and the ventilated middle ear cavity.
1495167 - Ventricular contractility evaluated by mechanical perturbation of the myocardium--exper...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Life sciences     Volume:  69     ISSN:  0024-3205     ISO Abbreviation:  Life Sci.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-09     Completed Date:  2001-07-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375521     Medline TA:  Life Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-80     Citation Subset:  IM    
Centre for Cardiovascular Science, University of Edinburgh, Dept of Biomedical Sciences, Scotland, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*,  physiology
Cardiovascular Agents / pharmacology
Coronary Circulation / drug effects*,  physiology
Endothelin-1 / pharmacology
Enzyme Inhibitors / pharmacology
Indomethacin / pharmacology
NG-Nitroarginine Methyl Ester / pharmacology
Rats, Sprague-Dawley
Urotensins / metabolism,  pharmacology*
Vasoconstrictor Agents / metabolism,  pharmacology*
Reg. No./Substance:
0/Cardiovascular Agents; 0/Endothelin-1; 0/Enzyme Inhibitors; 0/Urotensins; 0/Vasoconstrictor Agents; 50903-99-6/NG-Nitroarginine Methyl Ester; 53-86-1/Indomethacin; 9047-55-6/urotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Central and peripheral catecholamines regulate the exercise-induced elevation of plasma interleukin ...
Next Document:  Effect of St. John's wort on free radical production.